Immunoliposomes that optimize internalization into target cells

US7135177B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Christopher C. Benz · Novato, US
• Demetrois Papahadjopoulos · San Francisco, US
• John W. Park · North Palm Beach, US
• Keelung Hong · Mill Valley, US
• Dmitri B. Kirpotin · San Francisco, US

Key dates

• Filing date: Feb 28, 2001
• Grant date: Nov 14, 2006
• Expiry date: Feb 28, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab' domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.